Products from SYNkinase

SYNkinase

SYNkinase, headquartered in Australia, is a primary producer of research-use-only biomedical reagents, which it markets to life-science and drug-discovery researchers affiliated with universities, research institutes and industry. SYNkinase was established in 2008 by Professor Andrew Wilks and Dr. Xian Bu. The founders of the company have been involved in pharmaceutical drug discovery for three decades and have extensive scientific, company and board experience.

More information at: www.adipogen.com/synkinase

Go to the catalogs of SYNkinase

1 from 16 pages
No results were found for the filter!
SAR-020106
SAR-020106

Item number: SYN-1189-M001

Soluble in DMSO. SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC(50) of 13.3nM on the isolated human enzyme. This compound abrogates an etoposide-induced G(2) arrest with an IC(50) of 55nM in HT29 cells, and significantly enhances the cell killing of gemcitabine and SN38 by 3.0- to...
Keywords: SAR020106
Application: Chk1 inhibitor
CAS 1184843-57-9
MW: 382,9 D
From 250.00€ *
Review
GW-806742X
GW-806742X

Item number: SYN-1215-M001

Soluble in DMSO. Potent protein kinase VEGFR2 inhibitor (2nm range). Binds to the pseudokinase domain of MLKL and blocks cell death by necroptosis, as well. With regards to its role in necroptosis, it is an ATP-mimetic that was shown to bind recombinant mouse MLKL pseudokinase domain, which showed inhibited...
Keywords: GW806742X, AC1NS7PT, AGN-PC-0LQ49Y
Application: VEGFR2 inhibitor
CAS 579515-63-2
MW: 573,6 D
From 119.00€ *
Review
ABT-737
ABT-737

Item number: SYN-1001-M005

Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate...
Keywords: ABT737
Application: Bcl-2 / Bcl-X(L) / Bcl-w inhibitor
CAS 852808-04-9
MW: 813,4 D
From 79.00€ *
Review
SP2509
SP2509

Item number: SYN-1212-M001

Soluble in DMSO. LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1...
Keywords: SP-2509
Application: LSD1 inhibitor
CAS 1423715-09-6
MW: 437,9 D
From 158.00€ *
Review
Gefitinib
Gefitinib

Item number: SYN-1042-M001

Soluble in DMSO or ethanol. Gefitinib is a selective, orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. In NR6wtEGFR and NR6W cells, it inhibits Tyr1173, Tyr992, Tyr1173 and Tyr992 with IC(50) values of 37nM, 37nM, 26nM and 57nM, respectively. Target: EGFR , Kinase Group: RTK ,...
Keywords: ZD1839, Iressa
Application: EGFR inhibitor
CAS 184475-35-2
MW: 446,9 D
From 53.00€ *
Review
Vorinostat
Vorinostat

Item number: SYN-3006-M005

Solid. Soluble in DMSO or ethanol. Almost insoluble in water. Vorinostat (SAHA, MK0683, Zolinza) inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine...
Keywords: SAHA, MK0683, Zolinza
Application: HDAC inhibitor
CAS 149647-78-9
MW: 264,3 D
From 53.00€ *
Review
Tozasertib
Tozasertib

Item number: SYN-1092-M001

Soluble in DMSO or ethanol. In mammals, three Aurora kinases, Aurora A, Aurora B, and Aurora C, are expressed. Aurora C expression is mainly restricted to testis, where it functions during meiosis, whereas Aurora A and B play key functions regulating mitosis. Aurora A is localized to the centrosome and spindle...
Keywords: MK-0457, VX-680
Application: Aurora inhibitor
CAS 639089-54-6
MW: 464,6 D
From 66.00€ *
Review
H1152
H1152

Item number: SYN-1221-M001

Solid. Soluble in DMSO. H-1152 is a potent, specific, ATP-competitive and cell permeable ROCK inhibitor, with an IC50 of 12nM for ROCKII. H-1152 poorly inhibits PKA, PKC and myosin light chain kinase. Rho kinase (ROCK) activated by GTP-linked Rho phosphorylates targets that are involved in cytoskeletal remodelling,...
Keywords: (S)-4-Methyl-5-((2-methyl-1,4-diazepan-1-yl)sulfonyl)isoquinoline dihydrochloride, H1152
Application: Cell-permeable ROCK inhibitor
CAS 871543-07-6
MW: 392,3 D
From 106.00€ *
Review
MK-2206
MK-2206

Item number: SYN-1162-M005

Soluble in DMSO or ethanol. MK-2206 is a highly selective inhibitor of Akt1, Akt2 and Akt3 with IC(50) of 8nM, 12nM and 65nM, respectively. Target: AKT , Kinase Group: AGC , Substrate: Serine-Threonine
Keywords: MK2206
Application: AKT inhibitor
CAS 1032350-13-2
MW: 480,4 D
From 92.00€ *
Review
AZD-8055
AZD-8055

Item number: SYN-1166-M100

Soluble in DMSO or ethanol. AZD8055 is a novel ATP-competitive inhibitor of mTOR kinase activity with an IC(50) of 0.8nM. It shows excellent selectivity (~1,000-fold) against all class I phosphatidylinositol 3-kinase (PI3K) isoforms and other members of the PI3K-like kinase family. Target: mTOR , Kinase Group:...
Keywords: AZD8055, CCG168
Application: mTOR inhibitor
CAS 1009298-09-2
MW: 465,5 D
Please request pricing for this article.
Review
BMS-5
BMS-5

Item number: SYN-1024-M001

Soluble in DMSO. Kinases, such as LIM kinase 1 (LIMK1) and LIM kinase 2 (LIMK2), have been identified as participating in signal pathways affecting actin dynamics by deactivating cofilin. Over expression of LMK1 has been found in invasive breast and prostate cancer cell lines and suppression of LIMK 2 expression has...
Keywords: BMS5
Application: LIMK1 / LIMK2 inhibitor
CAS 1338247-35-0
MW: 431,3 D
From 106.00€ *
Review
GSK-1120212
GSK-1120212

Item number: SYN-1170-M010

Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. GSK1120212 (JTP-74057, trametinib) is a highly specific and potent MEK1 and MEK2 inhibitor with IC(50) values of 0.92nM and 1.8nM respectively. Target: MEK1 - MEK2 , Kinase Group: STE , Substrate: Serine-Threonine
Keywords: JTP-74057, GSK212, Trametinib
Application: MEK1 / MEK2 inhibitor
CAS 871700-17-3
MW: 615,4 D
From 106.00€ *
Review
1 from 16 pages